5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study. JAAD. 2024.
Published: 17 September 2024| Version 1 | DOI: 10.17632/xn73ym9348.1
Contributor:
Li-Chi ChenDescription
Supplemental methods and results.
Files
Categories
Pharmacoepidemiology, Breast Cancer, Dutasteride, Finasteride, Gynecological Cancer, Safety, Acne, Hair Loss, Gynecologic Dermatology